Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo.

A total of 562 patients who underwent randomization and received at least one dose of remdesivir or placebo were included in the analyses: 279 patients in the remdesivir group and 283 in the placebo group.

The mean age was 50 years, 47.9% of the patients were women, and 41.8% were Hispanic or Latinx.

The most common coexisting conditions were diabetes mellitus (61.6%), obesity (55.2%), and hypertension (47.7%).

COVID-19–related hospitalization or death from any cause occurred in 2 patients (0.7%) in the remdesivir group and in 15 (5.3%) in the placebo group (hazard ratio, 0.13; 95% confidence interval.

Read More